Immunoexpression status and prognostic value of mtor and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas

American Journal of Surgical Pathology

Volumn 35, Issue 10, 2011, Pages 1549-1556

  Schultz, Luciana ^a   Chaux, Alcides ^a   Albadine, Roula ^a   Hicks, Jessica ^a   Kim, Jenny J ^a   De Marzo, Angelo M ^a   Allaf, Mohamad E ^a   Carducci, Michael A ^a   Rodriguez, Ronald ^a   Hammers, Hans Joerg ^a   Argani, Pedram ^a   Reuter, Victor E ^b   Netto, George J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

4EBP1; AKT; c MYC; clear cell renal cell carcinoma; HIF 1 ; hypoxia induced pathway; mammalian target of rapamycin pathway; p27; PTEN; S6

Indexed keywords

HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S6; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL HYPOXIA; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; NEPHRECTOMY; PHOSPHORYLATION; PROGNOSIS; TISSUE MICROARRAY; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL HYPOXIA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PHOSPHORYLATION; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80053349980     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31822895e5     Document Type: Article

References (49)

1. Armengol G, Rojo F, Castellvi J, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res. 2007;67:7551-7555 (Pubitemid 47281345)
2. Baldewijns MM, van Vlodrop IJ, Schouten LJ, et al. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008;1785: 133-155
3. Brenner W, Farber G, Herget T, et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 2002;99: 53-57 (Pubitemid 34273197)
4. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893-2904 (Pubitemid 39602308)
5. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26:5630-5637
6. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res. 2010;16:88-98
7. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology. 2007;39:459-465 (Pubitemid 47450591)
8. Di Cristofano C, Minervini A, Menicagli M, et al. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol. 2007;31:1875-1881 (Pubitemid 350175815)
9. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, et al. Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene. 2004;23:7378-7390 (Pubitemid 39382140)
10. Dorevic G, Matusan-Ilijas K, Babarovic E, et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2009;28:40
11. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20:4368-4380 (Pubitemid 35266299)
12. Fan Y, Liu Z, Fang X, et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res. 2005;11:4331-4337 (Pubitemid 40825620)
13. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol Med. 2005;103:89-101
14. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205-38211 (Pubitemid 35154674)
15. Hager M, Haufe H, Kemmerling R, et al. PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology. 2007;39:482-485 (Pubitemid 47450589)
16. Hanna SC, Heathcote SA, Kim WY. mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther. 2008;8:283-292 (Pubitemid 351385918)
17. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37: 217-222
18. Hudes GR, Berkenblit A, Feingold J, et al. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009;36(Suppl 3):S26-S36
19. Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol. 2000;163:343-347
20. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300
21. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta. 2008;1784:150-158
22. Kim JH, Jung CW, Cho YH, et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep. 2005;13:859-864
23. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13: 7388-7393
24. Kozma L, Kiss I, Nagy A, et al. Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett. 1997; 111:127-131 (Pubitemid 27068227)
25. Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist. 2010;15:428-435
26. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16:1466-1471 (Pubitemid 34686328)
27. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295:858-861 (Pubitemid 34118367)
28. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol. 2007;17:303-308 (Pubitemid 47344615)
29. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275 (Pubitemid 29246458)
30. Minardi D, Lucarini G, Filosa A, et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol. 2008;21:447-455 (Pubitemid 351988410)
31. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540 (Pubitemid 29368255)
32. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxiainducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423-427
33. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267 (Pubitemid 46801555)
34. Patard JJ, Rioux-Leclercq N, Masson D, et al. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer. 2009;101:1417-1424
35. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729-734 (Pubitemid 44286004)
36. Schmidinger M, Zielinski CC. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treat Rev. 2009;35:289-296
37. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002; 196:186-193 (Pubitemid 34110900)
38. Sitaram RT, Cairney CJ, Grabowski P, et al. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma. Int J Cancer. 2009;125:783-790
39. Suarez C, Morales R, Munoz E, et al. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol. 2010;12:15-21
40. Tang SW, Chang WH, Su YC, et al. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett. 2009;273:35-43
41. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1-184. iii-iv
42. Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst. 1999;91:143-151 (Pubitemid 29042691)
43. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007; 177:1258-1263 (Pubitemid 46436019)
44. Viglietto G, Motti ML, Fusco A. Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle. 2002;1:394-400
45. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16:318-330 (Pubitemid 44311040)
46. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010;28:319-327
47. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851-864
48. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94:1569-1575 (Pubitemid 35277281)
49. Zbrozek AS, Hudes G, Levy D, et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics. 2010;28:577-584